Ads
related to: pamrevlumab for fibrosis mayo clinicassistantsage.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein. [2] This drug was developed by FibroGen, Inc. [3]
The drug, pamrevlumab, was being tested for idiopathic pulmonary fibrosis (IPF), which causes build up of scar tissue in the lungs, making them unable to transport oxygen into the bloodstream ...
Pamrevlumab [12] mab: human: connective tissue growth factor (CTGF) idiopathic pulmonary fibrosis (IPF), pancreatic cancer Panitumumab [69] Vectibix: mab: human: epidermal growth factor receptor (EGFR) Y: colorectal cancer: Pankomab: mab: humanized: tumor specific glycosylation of MUC1: ovarian cancer Panobacumab [98] mab: human: Pseudomonas ...
Pulmonary fibrosis is a condition in which the lungs become scarred over time. [1] Symptoms include shortness of breath , a dry cough, feeling tired, weight loss, and nail clubbing . [ 1 ] Complications may include pulmonary hypertension , respiratory failure , pneumothorax , and lung cancer .
Idiopathic pulmonary fibrosis; Other names: Fibrosing alveolitis, cryptogenic fibrosing alveolitis, diffuse fibrosing alveolitis, usual interstitial pneumonitis, diffuse interstitial pneumonitis: Figure A shows the location of the lungs and airways in the body. The inset image shows a detailed view of the lung's airways and air sacs in cross ...
Pulmonary fibrosis is not currently curable; but some steps can be taken to minimize its effects, such as changing the treatment regimen. Other measures that should be taken into account are quitting smoking (if applicable), oxygen therapy, pulmonary rehabilitation, vaccination against influenza and pneumococcus to prevent lung infections, or in extreme cases, a lung transplant.
Prognosis is related to the underlying disorder and the type and severity of lung disease. In severe cases, lung transplantation can be considered. This is more common in cases of bronchiolitis obliterans, pulmonary fibrosis, or pulmonary hypertension. Most complications are not fatal, but does reduce life expectancy to an estimated 5 to 10 ...
Pneumonitis describes general inflammation of lung tissue. [1] [2] Possible causative agents include radiation therapy of the chest, [3] exposure to medications used during chemo-therapy, the inhalation of debris (e.g., animal dander), aspiration, herbicides or fluorocarbons and some systemic diseases.
Ads
related to: pamrevlumab for fibrosis mayo clinicassistantsage.com has been visited by 10K+ users in the past month